The treatment for onchocerciasis is ivermectin (Mectizan®). Ivermectin paralyses and kills microfilariae, relieving intense skin itching and halting the progression towards blindness. It also prevents adult worms from producing more microfilariae for a few months following treatment, so reduces transmission Ivermectin is now considered to be the drug of choice for the treatment of onchocerciasis. The prognosis for people with onchocerciasis has changed greatly. It is now possible to avoid the heavy infection loads seen previously, and patients, especially expatriates, may have their symptoms relieved by treatment Moxidectin is an antiparasitic drug that was approved by the FDA in June 2018 to treat onchocerciasis in patients aged 12 years or older. The WHO initiated clinical trials for use in onchocerciasis.. Treatment WHO recommends treating onchocerciasis with ivermectin at least once yearly for between 10 to 15 years. Where O. volvulus co-exists with Loa loa, treatment strategies have to be adjusted Treatment The standard treatment for onchocerciasis is ivermectin (150-µ g/kg given orally ever 6 to 12 months). Ivermectin is a highly lipophilic [ 49 ], 16-membered macrocyclic lactone from Streptomyces avermitilis [ 50 ]
Onchocerciasis, or river blindness, is a neglected tropical disease (NTD) caused by the parasitic worm Onchocerca volvulus.It is transmitted through repeated bites by blackflies of the genus Simulium.The disease is called river blindness because the blackfly that transmits the infection lives and breeds near fast-flowing streams and rivers, mostly near remote rural villages Onchocerciasis is diagnosed by finding the parasites in skin nodules, skin biopsies, or skin scrapings. The treatment is the antiparasite drug ivermectin, given once or twice a year for about 10-15 years; the antibiotic doxycycline may also be utilized
The Onchocerciasis Treatment Market research report includes business growth, comprehensive analysis, and accurate statistics on revenue by the player for the forecast period 2021-2027 For treatment of onchocerciasis, ivermectin is given as a single dose by mouth and is repeated every 6 to 12 months until symptoms are gone. Ivermectin kills microfilariae, reducing the number of microfilariae in the skin and eyes. It reduces production of microfilariae by adult worms for several months Onchocerciasis is treated with an oral medicine called ivermectin. Ivermectin kills microfilariae, but not the adult worms. Treatment stops the progression of the disease. One dose of ivermectin every 3-12 months is required The apparent mutualistic dependency has also offered a novel approach to the treatment of onchocerciasis through the use of antibiotics to eliminate Wolbachia, delivering for the first time a treatment which has significant macrofilaricidal efficacy
Onchocerciasis is a rare tropical parasitic disease transmitted by a black fly. Infection by the parasite can cause eye and skin problems. In humans, the parasitic worms live under the skin (subcutaneous nodules) and produce larvae (microfilariae). The larvae are found throughout the body, but especially in the skin and eyes. [1 The most serious symptoms of river blindness are the result of repeated exposure to the parasites. This is why preventing future infections is an important part of treatment. There's no vaccine or drug that can prevent an onchocerciasis infection, but there are things you and whole communities can do to lower the odds of getting one
Treatment of onchocerciasis. Treatment of onchocerciasis consists in the use of ivermectin, diethylarbamazine and antripole. Ivermectin (mektizan) is prescribed to adults only once at a rate of 0.2 mg / kg. In the case of renewal of reproductive function in the filarias, the treatment is repeated after 3-4 weeks . It's considered safe for most people and only has to be taken once or twice a year to be effective Onchocerciasis is endemic in Africa, Yemen, and in small foci in Central America and South America. The burden of the disease has been reduced by prevention efforts, including control of the fly..
In mass drug administration (MDA) programmes, the treatment for onchocerciasis is ivermectin (trade name: Mectizan); infected people can be treated with two doses of ivermectin, six months apart, repeated every three years. The drug paralyses and kills the microfilariae causing fever, itching, and possibly oedema, arthritis and lymphadenopathy Onchocerciasis is an infestation by a roundworm in the Onchocerca family that lives in the nuchal ligament. Its larvae travel to the skin and cause severe itching. Onchocerciasis Average Cost. From 567 quotes ranging from $650 - $1,500. Average Cost Onchocerciasis Treatment Market Segmentation, History and Global Forecast 2021-2027. Infinity Business Insights announces the addition of new research analysis to the wide international database Onchocerciasis Treatment market to offer insightful views over the forecast period of 2021-2026. This Onchocerciasis Treatment report provides an in-depth analysis of the product pipeline and developer. Onchocerciasis Treatment. The goal of medical therapy is to eliminate the microfilarial stage of the condition to improve the symptoms and prevent further progression of the infection. A broad-spectrum anti-parasitic drug called ivermectin is normally given to the infected patients to paralyze and kill the larvae responsible for causing the.
Onchocerciasis treatment - The treatment is done by giving a patient a drug known as ivermectin. It is an antiparasitic drug that is given twice a year for around 10-15 years Treatment: It is difficult to treat onchocerciasis because no positive drugs are available till date for complete recovery from illness. Earlier diethylcarbamazine DEC was given but it was banned due to severe side effects. Surgical method of treatment involves risk of causing blindness. Even after surgery there is every chance for the survival. Author Summary River blindness (onchocerciasis) is transmitted by blackflies and causes severe itching, skin lesions, and vision impairment including blindness. More than 99% of all current cases are found in sub-Saharan Africa where the disease has historically hindered socioeconomic development in endemic areas. The treatment goal is shifting from control to elimination in Africa as. Onchocerciasis is a chronic and slowly progressive skin and eye disease caused by a worm called Onchocerca volvulus. It is one of the main causes of filariasis. O. volvulus is transmitted to humans through the bite of a blackfly (of the genus Simulium). Blackflies are found near fast-flowing rivers in the inter-tropical zones Community-directed treatment with ivermectin is the core strategy to eliminate onchocerciasis in Africa. In the Americas the strategy is biannual large-scale treatment with ivermectin. In July 2016, Guatemala became the fourth country in the world after Colombia (2013), Ecuador (2014), and Mexico (2015) to be verified free of onchocerciasis.
Background. Onchocerciasis is a debilitating vector-borne disease caused by the parasite, Onchocerca volvulus; transmitted by the bite of black-fly, Simulium damnosum .The disease is public health and socio-economic threat in many African countries [2,3].Worldwide there are more than 120 million people at risk of contracting the disease, while 18 million people are already infected Onchocerciasis, also known as river blindness, is the second leading cause of preventable blindness after trachoma. Onchocerciasis is an eye and skin infection caused by the parasitic worm, Onchocerca volvulus, which is transmitted by the bite of an infective blackfly (genus Simulium). Because the insect that spreads the disease breeds and lives near fast-flowing rivers and streams.
Onchocerciasis is an infection of a filarial worm which is endemic in Sub-Saharan Africa, including Ethiopia. Annual mass treatment with high coverage over for a long period of time should lead to a complete interruption of transmission and the ultimate elimination of the parasite. However, in Ethiopia, the required coverage levels were not achieved Onchocerciasis Treatment Market: Drivers and Restraints. Onchocerciasis treatment market has influenced the demand in recent years, soaring market capitalization of smaller players, rising number of strategic partnerships to scoop out the best of emerging medications or drugs, increased R&D spending by big pharma and emerging players, expanded. . Ocular lesions are always associated with onchocercal skin lesions (see Onchocerciasis, Chapter 6). - Pruritus, hemeralopia (crepuscular blindness), decrease in visual acuity, narrowing of the visual field, awareness of microfilariae in the visual field (the patient sees little wiggling worms before his. Onchocerciasis treatment. People who are found to be infected with river blindness should be treated in order to prevent the long-term skin damage and blindness. The recommended treatment is ivermectin, which will need to be given every 6 months for the life span of the adult worms or for as long as the infected person has evidence of skin or. Onchocerciasis in Animals. Onchocerciasis is a dermatitis in equines and ruminants caused by microfilariae produced by adult Onchocerca. The parasites are transmitted by various biting flies, and prevention is by topical repellent. Diagnosis can be performed by histology or skin scraping to identify the microfilariae
Onchocerciasis ('river blindness') has for several centuries been the scourge of people living in certain areas of the world where the disease is endemic. The treatment available up to 10 years ago, diethylcarbamazine, had very severe secondary effects. The availability of ivermectin — a well tolerated and highly effective microfilaricidal drug — has completely changed this scenario Onchocerciasis is a form of dermatitis that affects the horse's skin. When a horse is bitten by a gnat carrying onchocerca larvae, the larvae migrate through the bloodstream where they mature and release very small larvae known as microfilaria which then migrate to the skin resulting in an inflammatory reaction known as ventral midline dermatitis Treatment for onchocerciasis involves the eradication of microfilariae, as the current treatments that target adult worms are toxic for humans. Ivermectin is recommended for patients with the. Treatment of onchocerciasis is with the following medications: Ivermectin is an oral drug that is effective against microfilariae. It is given orally once in 6 months or once a year
Onchocerciasis is a filarial infection that causes skin lesions, rash, and, more importantly, eye disease, leading to visual impairment and sometimes blindness. Diagnose by slit-lamp examination of the eye and microscopic examination of a skin snip; where available, polymerase chain reaction (PCR) testing may be helpful Onchocerciasis is a neglected tropical disease which is still of immense major public health concern in several areas of Africa and the Americas. The disease manifests either as ocular or as dermal onchocerciasis with several symptoms including itching, nodules, skin thickening, visual impairment and blindness. Ivermectin has been an efficient microfilaricide against the causative agent of the. . 1 INTRODUCTION Onchocerciasis (river blindness) is a neglected tropical disease caused by Onchocerca volvulus , a parasitic nematode transmitted to humans through the bite of the blackfly. 1 The larvae.
The African Programme for Onchocerciasis Control (APOC) was launched in 1995 with the objective of controlling onchocerciasis as a public health and socio-economic problem in the 19 participating countries in Africa. 23 In 1997, it adopted Community-Directed Treatment with Ivermectin (CDTI) as its core strategy and coverage and compliance. The Ethiopian onchocerciasis control program decided to intensify interventions in the Wudi Gemzu hotspot (by quarterly ivermectin mass treatment) and to stop treatment in the surrounding area. A 20-km-wide buffer zone separated the area where treatment was stopped from other areas with potential ongoing transmission Disease Entity. Onchocerciasis ICD-9 125.3. This article focuses on the ophthalmic consequences of this systemic disease. Disease. Onchocerciasis (African River Blindness) is a filarial infection caused by the nematode Onchocerca volvulus—one of the nine worldwide filarial nematodes in which humans are the definitive host This paper presents a summary of reported cases of Serious Adverse Events (SAEs) following treatment with Mectizan® (ivermectin, Merck, Sharpe & Dohme) in onchocerciasis mass treatment programs from January 1, 1989 to December 31, 2001 through a passive surveillance system. A total of 207 SAE cases were reported out of approximately 165 million reported treatments delivered during the period.
#onchocerciasis #volvulusonchocerciasis | River blindness | Life cycle, symptoms and treatment | Bio scienceOnchocerciasis is an eye and skin disease caused. The apparent mutualistic dependency has also offered a novel approach to the treatment of onchocerciasis through the use of antibiotics to eliminate Wolbachia, delivering for the first time a treatment which has significant macrofilaricidal efficacy Onchocerciasis treatment market is segmented of the basis of treatment, drugs, route of administration, distribution channel and end-users. The growth among these specific segments will help users analyze niche pockets of growth and strategies to approach the market and determine your core application areas and difference in your target markets 1.3 Onchocerciasis elimination programmes and their phases..... 2 1.4 Description of diagnostic tests offi cially confi rmed as having successfully completed a post-treatment surveillance period of at least 3-5 years of interrupted transmission in all its previously endemic onchocerciasis foci It emerged in 1988 as a treatment for a potentially vision-harming disease called onchocerciasis. The drug now is recognized as one of the greatest medical accomplishments of the 20th century, according to an article published in 2011 in a scientific journal
Author summary Onchocerciasis, also known as river blindness, is the second most common infectious cause of blindness worldwide, but also leads to serious skin conditions. Large-scale interventions are ongoing to control and eliminate the disease in Africa, yet the impact of these interventions on onchocercal morbidity is largely unknown. Here, we predict the trends in a wide spectrum of skin. Ivermectin-based preventive chemotherapy (PC) is distributed annually to all at-risk populations eligible for ivermectin treatment to control and/or eliminate onchocerciasis. Information on the impact of mass ivermectin administration on onchocerciasis transmission is scanty, and it is tricky to appreciate the progress towards elimination and engage corrective measures
The ocular changes that occur with diethylcarbamazine treatment of onchocerciasis seriously restrict its usefulness. Ivermectin, a newly developed antifilarial drug, was compared with diethylcarbamazine for treatment of onchocerciasis in a double-masked, placebo-controlled trial. Thirty men with moderate to severe infection and ocular. Onchocerciasis and loiasis are caused by infection with filarial worms. Severe skin and eye lesions, and blindness are found in onchocerciasis, and the disease is an important public health problem in endemic areas. Loiasis causes Calabar swelling and 'eye worm,' whose public health significance is yet to be clarified Background . Community-directed treatment with ivermectin twice a year is a major action to control onchocerciasis in endemic countries. Even though the community-directed treatment with ivermectin was proven effective in treating the disease, the level of compliance to the treatment and its contributing factors was not well addressed in our study area
Abstract. We compared ivermectin with diethylcarbamazine for the treatment of onchocerciasis in a double-blind, placebo-controlled trial. Thirty men with moderate to heavy infection and ocular. Anthelmintic treatment is considered necessary in all affected dogs in order to achieve a disease free state. References. Sanchez MD, Orita VM, Nolan TJ. Pathology in practice. JAVMA 2012; 240: 385-387. Zarfoss MK, Dubielzig RR, Eberhard ML, et al. Canine ocular onchocerciasis in the United States: two new cases and a review of the literature View messages from patients providing insights into their medical experiences with Onchocerciasis - Symptoms and Signs. Share in the message dialogue to help others and address questions on symptoms, diagnosis, and treatments, from MedicineNet's doctors Endosymbiotic Wolbachia bacteria in the worms are targets for a new therapeutic approach Onchocerciasis, or river blindness, caused by the filaria Onchocerca volvulus , affects more than 17 million people in Africa, Latin America, and Yemen. The microfilaricidal agent ivermectin is the principal means of controlling the disease, through mass treatment Introduction Onchocerciasis is targeted for elimination mainly with annual community-directed treatment with ivermectin (CDTI). High infection levels have been reported in South-West Cameroon, despite ≥15 years of CDTI. The aim of this study was to assess factors associated with continued onchocerciasis transmission and skin disease. Methods A large-scale cross-sectional study was conducted.
Effects of visual field loss. Most common causes of blindness. Onchocerciasis and the skin (1) Onchocerciasis and the skin (2) Onchocerciasis and the brain. Onchocerciasis treatment/control mechanisms. Destroying the adult filaria. Use of a microfilaricide. Eliminating the vector The Onchocerciasis Treatment Market research report thoroughly explains each and every aspect related to the Global Onchocerciasis Treatment Market, which facilitates the report's reader to study and evaluate the upcoming market trend and execute the analytical data to promote the business.. Onchocerciasis Treatment Market Insight: Onchocerciasis treatment market is growing at a steady CAGR. Onchocerciasis or river blindness is endemic in many sub-Saharan African countries, with minor foci in Central and South America and the Yemen .It is estimated to affect over 37 million people , of whom 500,000 have been visually impaired and 270,000 blind.The registration of ivermectin as a drug for the treatment of onchocerciasis in 1987 raised great hopes for onchocerciasis control in. Onchocerciasis is a major blinding disease affecting at least 28 million people in Africa and Latin America. Although a large-scale vector control program has been highly successful in limiting transmission of infection in West Africa, there has not been a satisfactory form of treatment available for those already infected or those living in other areas
However, the efficiency of using doxycycline in mass treatment campaigns has been questioned. Surgical Care Removal of all subcutaneous nodules can be curative; however, many nodules are difficult to find. Background Onchocerciasis is a chronic parasitic disease caused by the filarial nematode Onchocerca volvulus Goals for elimination of the disease. Current available treatment has not permitted elimination of the transmission of onchocerciasis. Moxidectin is a new promising treatment which could substantially reduce transmission of the parasite between annual treatments and thus decrease the number of years of treatments required to achieve parasite elimination In onchocerciasis, it has been established that treatment with doxycycline at 100 mg per day for six weeks leads to the long-term sterility of adult female worms 22, 23. This effect is probably permanent because there is no evidence for the reappearance of Wolbachia or for the resumption of embryogenesis in a large series of extirpated. Annual treatment has been the principal treatment strategy for onchocerciasis control in Africa and it has also already achieved interruption of transmission and elimination of infection in several foci. However, the success of annual treatment does not exclude the use of other intervention strategies for specific purposes This treatment kills only the larvae, which successfully alleviates the cutaneous symptoms of onchocerciasis, but it does not kill adult worms. Following a period of temporary sterility, the adult worms may resume production of larvae, which cause symptoms to return, requiring repeated treatment every 6-12 months
It has FDA approval for the treatment of strongyloides and onchocerciasis in the United States, other use is termed 'off label'. In treatment of scabies its use may be appropriate in selected cases where topical therapy is impractical or has failed and is particularly useful in cases of crusted scabies (also called 'Norwegian' scabies) yearly treatment in endemic areas, provided free of charge from the manufacturer, costs of distribution and the sustainability of control efforts at all levels have presented obstacles to realizing the potential value of community treatment. Annual treatment is required over many years. The most important consequence of onchocerciasis i Ghana For Specific Travellers: River Blindness Description. River Blindness, also known as Onchocerciasis, is caused by the Onchocerca volvulus worm which is transmitted from person to person by daytime biting infected blackflies belonging to the genus Simulium damnosum.Infective larval worms (microfilariae) develop in the blackfly and once injected into humans through a blood meal, the worms. Medicinal plants for onchocerciasis treatment. Type. Compound (s) The University of Buea has experience of investigating crude plant extracts for selective activity in the search for novel filaricides To eliminate onchocerciasis as a disease of public health importance within a period of 12-15 years by effective and sustainable ivermectin treatment. Eliminate vector in isolated foci Angola, Burundi, Cameroon, Central African Republic, Chad, Democratic Republic of Congo, Equatorial Guinea, Ethiopia, Gabon, Kenya, Liberia, Malawi, Mozambique.
Onchocerciasis is a leading cause of blindness worldwide, hence elimination of the infection is an important health priority. Community-based treatment programs with ivermectin form the basis of control programs for the disease in Latin America. The long-term administration of ivermectin could eliminate Onchocerca volvulus infection from endemic areas in Latin America Case study: Onchocerciasis treatment. Two of the three lectures of the fourth week reflect on various attempts to combat Onchocerciasis - the so-called river blindness (see explanations below). This parasitic disease can be treated with the drug Ivermectin, which has to be applied long-term (for about 15 years) to be effective Introduction . Moxidectin is a milbemycin endectocide recently approved for the treatment of human onchocerciasis. Onchocerciasis, earmarked for elimination of transmission, is a filarial infection endemic in Africa, Yemen, and the Amazonian focus straddling Venezuela and Brazil The treatment available up to 10 years ago, diethylcarbamazine, had very severe secondary effects. The availability of ivermectin--a well tolerated and highly effective microfilaricidal drug--has completely changed this scenario. Ivermectin is now considered to be the drug of choice for the treatment of onchocerciasis Onchocerciasis control needs 90% treatment coverage of ivermectin . Though CLTI adherence plays a key role in the success of onchocerciasis control, sustained attention is not given in endemic area of Ethiopia. Unless adherence to the drug administration is guaran-teed, the control of onchocerciasis would not be effect-ive
Onchocerciasis is a parasitic disease caused by the filarial nematode worm Onchocerca volvulus. It is transmitted to humans by black flies (genus Simulium) and can cause severe skin and eye disease, including blindness. The disease is commonly known as river blindness because the larvae of the blackfly vectors breed in fast flowing rivers.Onchocerciasis is endemic in Africa, and in 13 foci. Treatment of onchocerciasis or lymphatic filariasis has been thwarted by concerns of serious complications related to the presence of L. loa infection. This report shows that leveraging digital tec.. Detailed Description: This study will provide preliminary data on the safety of IDA treatment in persons with onchocerciasis when it is administered after pre-treatment with IVM to clear or greatly reduce microfilariae from the skin and eyes. Widespread use of IDA following IVM pretreatment (I/IDA) has the potential to greatly accelerate. Onchocerciasis, which is an infectious disease caused by the helminth Onchocerca volvulus, affects some of the world's most disadvantaged communities, 99% of which are in remote, rural areas in sub-Saharan Africa. Infective larvae, transmitted by the bite of Simulium spp, develop into macrofilariae that reside in subcutaneous and deep tissue nodules, and produce millions of microfilariae.
Onchocerciasis is a potentially serious disease that occurs mostly in Africa and South America. If you want to learn more about the causes, symptoms, and treatment of this disease, then you came. The fifth edition of the Standard Treatment Guidelines is aimed at all levels of healthcare, both in the public and private sectors, throughout the country and will assist healthcare professionals in their treatment choices Care was taken in the process of the review of the fourth edition to ensure a guide that will be acceptable and useful to all Ivermectin for river blindness (onchocerciasis) Onchocerciasis is caused by tiny worms and is transmitted from person to person by a small biting fly. The fly breeds in fast flowing rivers and streams mainly in West Africa. The disease causes severe itching and thickening of the skin and damages structures at the front and back of the eye Perceptions towards onchocerciasis and ivermectin treatment . Out of 422 respondents, 321 (76.1%) agreed or strongly agreed that onchocerciasis is a common health problem in their community (Table 5). A majority [308 (73%) and 315 (74.1%) respectively] agreed that onchocerciasis is a dangerous disease and a curable disease
Onchocerciasis, also known as river blindness, is a disease caused by the parasite Onchocerca volvulus and transmitted by infected blackflies living near rivers or fast-moving streams in Africa. Onchocerciasis is the world's fourth leading cause of preventable blindness and infects 26 million people, 99 percent of whom live in sub-Saharan. Onchocerciasis, commonly known as 'river blindness', is a debilitating vector-borne disease caused by a parasite, Onchocerca volvulus [1, 2] and transmitted by the bite of black-fly, Simulium damnosum, which breeds in fast flowing streams and rivers .Adult worms dwell in subcutaneous nodule, from where fertilized females produce millions of microfilariae (mf) which live and freely. A deterministic model of onchocerciasis disease dynamics is considered in a community partitioned into compartments based on the disease status. Public health education is offered in the community during the implementation of mass treatment using ivermectin drugs
The Food and Drug Administration (FDA) has approved moxidectin for the treatment of onchocerciasis (river blindness) due to Onchocerca volvulus in patients ≥12 years of age.. Moxidectin, a. TREATMENT. Ivermectin is the drug of choice. Repeated annual or semiannual doses may be required to control symptoms, as the drug kills the microfilariae but not the adult worms. Onchocerciasis—guidelines for stopping mass drug administration and verifying elimination of human onchocerciasis—criteria and procedures annexes. WHO Document. Introduction. Human onchocerciasis, also known as 'river blindness', is a parasitic infection caused by the filarial nematode Onchocerca volvulus.It is transmitted by the bites of Simulium blackflies. Of the 120 million people at risk, 99% live in sub-Saharan Africa, although the disease has also been endemic in six countries of Latin America and is present in Yemen 1 Study reveals onchocerciasis can be eliminated by adapting new measures and tools. Download PDF Copy. Reviewed by Emily Henderson, B.Sc. Dec 15 2020. A report on onchocerciasis (also known as. Background Onchocerciasis (river blindness) is endemic mostly in remote and rural areas in sub-Saharan Africa. The treatment goal for onchocerciasis has shifted from control to elimination in Africa. For investment decisions, national and global policymakers need evidence on benefits, costs and risks of elimination initiatives. Methods We estimated the health benefits using a dynamical.
View messages from patients providing insights into their medical experiences with Onchocerciasis - Symptoms and Signs. Share in the message dialogue to help others and address questions on symptoms, diagnosis, and treatments, from MedicineNet's doctors Onchocerciasis is a disease that is caused by Onchocerca volvulus, which is a parasitic worm found near rivers mostly in Africa and South America. Symptoms of this disease include itchy skin, dark. Onchocerciasis. STROMECTOL (ivermectin) is indicated for the treatment of onchocerciasis due to the nematode parasite Onchocerca volvulus. This indication is based on randomized, double-blind, placebo-controlled and comparative studies conducted in 1427 patients in onchocerciasis-endemic areas of West Africa
treatment of onchocerciasis with ivermectin (CDTI) and its long-term e ect on parasitological and clinical changes. Previous studies have indicated encouraging potential of breaking the disease transmission cycle in some foci in Latin American countries such as Mexico and Guatemala in which biannual treatment was practiced [ ]. It wil Onchocerciasis, also known as River blindness is an eye and skin infection caused by the parasitic worm Onchocerca volvulus. It is considered to be among the list of neglected tropical diseases. According to the CDC a neglected tropical diseases are a group of parasitic and bacterial diseases that attribute to substantial illness for more. Treatment The goal of treating onchocerciasis is to eliminate the microfilarial stage of the disease to improve symptoms, eliminate progression of eye lesions and most importantly, to prevent or interrupt transmission or spread of the disease. Ivermectin. This is a drug of choice used for treating onchocerciasis The progress of mass, community-directed, treatment with ivermectin (CDTI) for onchocerciasis control was disrupted by severe adverse effects (SAE) in the Democratic Republic of Congo (DRC). The study aimed at determining the frequency of post-CDTI SAE as well as factors associated with the occurrence of SAE. Our retrospective study relied on SAE collection cards, as archived by the DRC.